Minimal clinically important differences in average, best, worst and current intensity and unpleasantness of chronic breathlessness.

Like Comment
Chronic breathlessness has devastating consequences. The minimal clinically important difference (MCID) for current intensity has been estimated as 9 mm on a 100 mm visual analogue scale (VAS). We aimed to determine MCIDs for commonly used dimensions and recall periods: the current unpleasantness and current, average, best and worst intensity of the last 24 h for chronic breathlessness.This was a secondary analysis of a randomised controlled trial of morphine versus placebo during seven days in people with chronic breathlessness from severe disease. The breathlessness scores were self-reported using a diary each evening on 100 mm VAS. The MCID for improvement in each score was estimated using anchor based and distribution based methods.283 participants (mean age 74.2 years; 63% males; 58% COPD; 87.0% mMRC 3-4) were included. Anchor-based MCIDs for breathlessness scores ranged from -13.9 mm to -9.5 mm. The MCIDs were similar when using different anchors and across all participants, and participants with more severe BREATHLESSNESS (mMRC 3-4), respectively. Distribution based effect sizes were: small (-4.7 to -6.3 mm), moderate (-9.4 to -12.5 mm) and large effect (-15.0 to -20.0 mm). Sample sizes for trials using the different scores were proposed. MCIDs of absolute change were more stable than using relative change from baseline.An improvement of about 10 mm on a 100 mm VAS is likely to be clinically meaningful across commonly used measures of chronic breathlessness (current intensity, unpleasantness, and average, best and worst intensity over the last 24 h) - to evaluate clinical benefit and effects in therapeutic trials.


Click here to read the full article @ The European respiratory journal

ClinOwl

The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
2841 Contributions
1 Followers
0 Following

No comments yet.